Acral Melanoma Incidence and Survival Trends in 1990-2020: A Nationwide, Population-based Study.


Journal

Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310

Informations de publication

Date de publication:
14 Aug 2024
Historique:
received: 04 03 2024
accepted: 24 06 2024
medline: 14 8 2024
pubmed: 14 8 2024
entrez: 14 8 2024
Statut: epublish

Résumé

Acral melanoma is a clinical subtype of melanoma with high mortality, on which research is limited in scope. This study aimed to assess incidence trends and melanoma-specific survival rates for acral melanoma in the Swedish population from 1990 to 2020.This cross-sectional study included patients with an acral melanoma diagnosis from 1990 to 2020 from the nationwide, population-based Swedish Melanoma Registry. Analyses on acral melanoma melanoma-specific survival rates were adjusted for age, sex, histopathological subtype, and tumour thickness. Clinicopathological features and melanoma-specific survival rates were compared between diagnostic periods: 1990-1999, 2000-2009, and 2010-2020, respectively. Changes in standardized incidence rates in 1996-2020 were evaluated separately for males and females. In total, 1,000 acral melanomas in 999 patients were included in the study. No significant yearly change in standardized incidence rates for either males or females was observed, even though the absolute number of cases increased. Factors such as male sex, age ≥ 70 years, and Breslow thickness > 1.0 were independently linked to lower melanoma-specific survival. The 5-year melanoma-specific survival across the studied period ranged from 75.8% to 77.9% for females, and from 62.4% to 71.7% for males.

Identifiants

pubmed: 39140487
doi: 10.2340/actadv.v104.40242
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

adv40242

Auteurs

Teo Helkkula (T)

Department of Clinical Sciences Lund, Lund University Skin Cancer Research Group, Lund University, Lund, Sweden, Department of Dermatology and Venereology, Skåne University Hospital, Lund, Sweden. teo.helkkula@med.lu.se.

Gustav Christensen (G)

Department of Clinical Sciences Lund, Lund University Skin Cancer Research Group, Lund University, Lund, Sweden, Department of Dermatology and Venereology, Skåne University Hospital, Lund, Sweden.

Rasmus Mikiver (R)

Clinical and Experimental Medicine, Linköping University, Linköping, Sweden Regional Cancer Centre Southeast Sweden, Linköping, Sweden.

Åsa Ingvar (Å)

Department of Clinical Sciences Lund, Lund University Skin Cancer Research Group, Lund University, Lund, Sweden, Department of Dermatology and Venereology, Skåne University Hospital, Lund, Sweden.

Karolin Isaksson (K)

Department of Clinical Sciences Lund, Lund University Skin Cancer Research Group, Lund University, Lund, Sweden; Department of Surgery, Kristianstad Hospital, Kristianstad, Sweden.

Kari Nielsen (K)

Department of Clinical Sciences Lund, Lund University Skin Cancer Research Group, Lund University, Lund, Sweden, Department of Dermatology and Venereology, Skåne University Hospital, Lund, Sweden; Department of Dermatology, Helsingborg Hospital, Helsingborg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH